BiomX Inc.: Fourth Quarter and Full Year 2024 Financial Results and Business Updates
NESS ZIONA, Israel, March 19, 2025 – BiomX Inc. (NYSE American: PHGE), a pioneering clinical-stage biotech company specializing in the development of novel natural and engineered phage therapies that specifically target pathogenic bacteria, has announced that it will release its fourth quarter and full-year 2024 financial results and deliver business and program updates on Tuesday, March 25, 2025. This announcement comes as BiomX continues to advance its innovative approach to combating antibiotic-resistant bacteria and addressing unmet medical needs.
Company’s Progress
BiomX’s dedication to phage therapy, a promising alternative to traditional antibiotics, has gained significant momentum in recent years. The company’s unique approach involves the use of natural and engineered bacteriophages, viruses that infect and eliminate specific bacteria, to combat antibiotic-resistant infections. BiomX’s pipeline includes several promising programs, including:
- BX001: A phage therapy candidate for the treatment of Clostridioides difficile infection (CDI), a common and often recurring infection that can cause severe diarrhea and other complications. BiomX has completed a Phase 1b clinical trial for BX001 and is planning to initiate a Phase 2 trial in the first half of 2025.
- BX014: A phage therapy candidate for the treatment of Pseudomonas aeruginosa infections, which can lead to chronic lung infections in cystic fibrosis patients and other individuals with compromised immune systems. BiomX expects to initiate a Phase 1 clinical trial for BX014 in mid-2025.
Impact on Individuals
For individuals who struggle with antibiotic-resistant infections, the progress of BiomX and other phage therapy companies represents a potential game-changer. Antibiotic-resistant bacteria pose a significant threat to public health, leading to increased morbidity and mortality, longer hospital stays, and higher healthcare costs. Phage therapy offers a potential solution to this growing problem by using viruses specifically designed to target and eliminate bacteria, without the risk of developing resistance. This approach could lead to more effective treatments for a range of infections, including CDI, P. aeruginosa, and others.
Impact on the World
The potential impact of BiomX’s progress on the world extends beyond individual health. Antibiotic-resistant bacteria pose a significant threat to global health security, as they can spread rapidly and easily between individuals and communities, leading to outbreaks and pandemics. The World Health Organization (WHO) has identified antibiotic resistance as one of the biggest threats to global health, food security, and development. The development of effective phage therapies could help combat this threat, enabling more effective treatment of antibiotic-resistant infections and reducing the overall burden on healthcare systems.
Conclusion
BiomX’s announcement of its fourth quarter and full-year 2024 financial results and business updates marks an exciting time for the company and the field of phage therapy as a whole. With several promising programs in development, BiomX is well-positioned to make a significant impact on the treatment of antibiotic-resistant infections. For individuals dealing with these infections, the potential for more effective treatments represents a hopeful development. For the world, the progress of BiomX and other phage therapy companies could help combat the growing threat of antibiotic resistance and improve global health security.
As BiomX and other companies continue to advance phage therapy, it is essential to stay informed about their progress and the potential implications for individual and global health. By working together, we can help ensure that these innovative treatments reach those who need them most and contribute to a healthier, more resilient world.
